NATERA INC (NTRA)

First Week of June 21st Options Trading For Natera (NTRA)

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

NATERA INC is showing promising signs of setting up for a breakout.

NATERA INC is setting up nicely for a breakout.

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer

New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease

Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers

Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan

Agilent Technologies Stock Getting Closer To Key Technical Benchmark

Agilent Technologies stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 65 to 71.

Natera to Participate in March Investor Conferences

Natera Reports Fourth Quarter and Full Year 2023 Financial Results

Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests

Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer

Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy

NVTA stock tumbled yesterday amid a report that the firm could declare bankruptcy soon. The shares were halted for news pending. 

New Study Validates Signatera™ in Endometrial Cancer

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

CareDX pares loss, gains after jury awards $96M to Natera in patent dispute

CareDX (CDNA) stock dropped 5% in premarket trading after a jury awarded $96.3 million to Natera (NTRA) in a patent dispute, causing a total 22% decline.

CareDX stock slide continues after jury awards $96.3M to Natera in patent dispute

CareDX (CDNA) stock dropped 5% in premarket trading after a jury awarded $96.3 million to Natera (NTRA) in a patent dispute, causing a total 22% decline.

Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties